Article Type
Changed
Thu, 01/10/2019 - 12:04
Display Headline
Discrete Papular Form of Lichen Myxedematosus: A Case Report and Review of the Literature

Lichen myxedematosus (LM), also called papular mucinosis, was first described by Dubreuilh1 in 1906 and later classified by Montgomery and Underwood2 in 1953. LMs are a group of localized or generalized papular eruptions of unknown etiology categorized as cutaneous mucinoses in which dermal mucin deposition is the distinctive histologic feature.3-5 LM has no relation to endocrine gland disorders, particularly thyroid disease.2,3,6 In their landmark paper, Montgomery and Underwood2 classified 4 clinical types of LM: (1) generalized lichenoid papular eruption, which is also called scleromyxedema, (2) discrete papular form, (3) localized to generalized lichenoid plaques, and (4) urticarial plaques and nodular eruptions that usually evolve into the generalized lichenoid form. In 2001, Rongioletti and Rebora6 updated the classification system. The articles by Montgomery and Underwood2 and Rongioletti and Rebora6 both agree with the existence of the discrete papular form, also called discrete papular LM (DPLM). According to Rongioletti and Rebora,6 DPLM has only been reported in the medical literature 8 times,1,2,7-12 This is unlike scleromyxedema, the most common type of LM, which has been documented in more than 110 cases.6 In this case report, we describe an interesting case of DPLM that was localized to the neck of our patient, and we review the English medical literature. 


Case Report

An 80-year-old black woman presented to our clinic with a 2-month history of a pruritic eruption localized to her neck. Multiple topical steroids and antihistamines had been used without any decrease in the eruption or the pruritus. The woman's medical history was significant for gastric cancer status post a partial gastrectomy 7 years prior, pseudotumor cerebri, hypertension, and osteoporosis. She is followed regularly for these conditions, which are stable. Her medications included acetazolamide, atenolol, nifedipine, rabeprazole sodium, fluoxetine, oxybutynin chloride, alendronate sodium, docusate calcium, and a multivitamin. Prior to the onset of this eruption, the patient had a change in the acetazolamide formulation, which was initially thought to be the culprit. Although she returned to the original formulation for longer than a month, she had no resolution of the symptoms. At that time, she sought evaluation in our clinic. On physical examination, multiple 2- to 4-mm discrete, flesh-colored shiny papules without scale were present over the patient's bilateral and posterior neck (Figure 1). Results of 2 punch biopsies showed splaying of the collagen with mucin present diffusely throughout the dermis. No increase in the number of fibroblasts was seen (Figure 2). Results of colloidal iron stain showed positive results in the papillary dermis and showed mucin mildly throughout the deep dermis (Figure 3), supporting the diagnosis of LM. Complete blood count, chemistry panel, liver function, thyrotropin, and serum protein test results were all within reference range. Pimecrolimus cream has been effective in treating our patient's pruritus. We have followed her for 14 months, and the lesions have remained localized to her neck, with continued normal thyrotropin and serum protein values.


Comment

In 2001, Rongioletti and Rebora6 revised the classification system of LM, categorizing it into 3 broad subsets: (1) generalized papular and sclerodermoid, (2) localized LM, and (3) atypical forms. The first subset, generalized papular and sclerodermoid, represents scleromyxedema. Diagnosis requires a generalized papular and sclerodermoid eruption, monoclonal gammopathy (paraproteinemia), no evidence of thyroid dysfunction, and a histologic triad of fibroblast proliferation, fibrosis, and mucin deposition.6 Scleromyxedema is associated with many systemic disorders that may include numerous organ systems.6,13 Although spontaneous resolution has been reported,14 scleromyxedema typically is a long-term and disfiguring disease6,13 associated with variable morbidity and mortality.15,16 The criteria for diagnosing the subset of localized LM requires a papular eruption, deposits of mucin with variable fibroblast growth, absence of paraproteinemia, and absence of thyroid dysfunction.6 There are 5 subtypes6: DPLM,2,7-9,17-21 acral persistent papular mucinosis (APPM),22-27 cutaneous mucinosis of infancy,28-31 self-healing papular mucinosis (SHPM),32-36 and nodular LM.37,38 All subtypes show small, firm, waxy papules limited to a few areas of the skin, which may coalesce and form nodules or plaques. DPLM can involve any site on the body. APPM exclusively involves both extensor surfaces of the distal upper extremities. Cutaneous mucinosis of infancy is a pediatric variant of DPLM or APPM. SHPM has spontaneous resolution. Nodular LM is characterized by a predominance of nodules.6 All subtypes except for SHPM typically persist long-term. Systemic symptoms were only reported in SHPM.32,33 In general, localized LM is self-limited and associated with a good prognosis.6 The histologic features of LM are summarized in Table 1.5 The pathology lies within the dermis for all types of this disease, and the epidermis is essentially normal.5 The types of LM can be distinguished from one another by 3 histologic clues: (1) mucin distribution pattern, (2) dermal level of mucin deposits, and (3) some extra findings.5 Differentiation can be additionally aided by observing the number of fibroblasts. Common mucin stains include colloidal iron, mucicarmine, and alcian blue at pH 2.5 (but not pH 0.5); common metachromatic mucin stains include toluidine blue, thionine, and methylene blue.3

 

 

DPLM is a subtype of localized LM.2,6 Although the lesions can involve any site, DPLM is typically distributed symmetrically to the trunk and limbs. The skin lesions have been described as a variable number of firm, smooth, waxy, or flesh-colored papules 2 to 5 mm in size. Normal serum protein and thyroid function test results verify the diagnosis of DPLM.6 Because Montgomery and Underwood2 originally defined LM as having no relation to any endocrine gland disturbance, we recommend additional random chemistry panel or fasting blood glucose laboratory tests if there is any question that a patient may have diabetes mellitus. Histologically, DPLM may have a diffuse or local pattern of mucin distribution involving the upper and mid reticular dermis. The involved dermis typically shows edema. The amount of fibroblast proliferation is variable. When compared with scleromyxedema, DPLM has no collagen deposition or sclerosis and a lesser amount of fibroblast proliferation.5-7 Some argue that DPLM and APPM are closely related variants.25,27 However, we believe that DPLM and APPM are distinct subtypes of localized LM. DPLM typically affects men (Table 2) and its lesions may be erythematous, larger, and include areas other than the distal upper extremities.4,23,24 In comparison, APPM has an overwhelming female-to-male ratio of 4.7:1.6 APPM also exclusively involves the back of the hands, extensor surface of the wrists, and sometimes the distal forearms.4,6,23 Histologically, APPM typically has more focal mucin deposits, which spare a subepidermal grenz zone, and a normal number of fibroblasts; DPLM has mucin deposits that are more diffuse (compared with APPM), have a variable number of increased fibroblasts, and have an irregular arrangement of collagen bundles.4-6,23

Table 2 summarizes the main features of the 10 DPLM cases reported in the English medical literature.2,7-9,17-21 Our criteria required there be no evidence of paraproteinemia, no history or laboratory evidence of any endocrine disease, no history of human immunodeficiency virus infection, histologic proof of dermal mucin deposits, and specific gross descriptions consistent with DPLM. It should be noted that only 4 of the 8 DPLM cases originally cited by Rongioletti and Rebora6 were included in Table 2. Four cases were excluded because 2 reports were written in French,1,12 1 report included a patient with diabetes mellitus,10 and another did not perform a necessary laboratory test to rule out thyroid disease.11 Other cases were excluded because they did not fulfill our criteria.39,40 Among the 10 DPLM patients summarized, 7 were men. The mean age of the group was 51.3 years. Only 3 of the 10 cases reported information on the patient's ethnicity: one was Caucasian,7 one was Asian,8 and our patient was African American. Nine of the 10 cases reported no evidence of paraproteinemia. The single case2 that did not report this finding was published before an association between LM and paraproteinemia was known in the 1960s.41 All 10 cases reported thyroid function test results within reference range. Only 3 of the 10 patients had symptomatic skin lesions, which were mainly pruritus. No systemic symptoms were noted. Three of the 10 patients had solitary skin lesions on areas other than the typical trunk and limbs. One patient had skin lesions only on his lumbar region, another had facial lesions, and our patient had lesions on her neck. Seven of the 10 patients had comorbid medical disorders, including hypertension, migraines, psoriatic erythroderma, psoriasis, seizures, gastric cancer in remission, pseudotumor cerebri, osteoporosis, and hepatitis C. Only hepatitis C was comorbid with more than one DPLM patient.17,20 This may be a coincidence because one patient developed DPLM after contracting hepatitis C,20, while the other patient developed it before contracting hepatitis C.17 Psychiatric illness was limited to depression and was found in 2 cases.20,21 No DPLM cases progressed to scleromyxedema, and none have been reported in the literature.5,6 DPLM rarely resolves on its own. Spontaneous resolution did not occur in any of the 10 reported DPLM cases, and only 2 patients were treated successfully. In Reynolds et al,18 the patient responded to therapy with intralesional corticosteroid injections and flurandrenolide-impregnated tape. In Kaymen et al,19 a patient was treated with a CO2 laser and postoperative intralesional corticosteroid injections. There was no growth after one year. All the other DPLM cases did not have effective therapy, lacked specific details of improvement, or did not report this information.2,7-9,17,20,21 Only Tay and Khoo,8 Enerback and Mobacken,9 and Kaymen et al19 commented on which therapies failed (oral thyroxine, topical corticosteroids, and shave excision, respectively). Our patient complained of persistent itching that did not respond to initial treatment with topical steroids and antihistamine medications. She later received pruritic relief with pimecrolimus cream therapy. However, the skin lesions remained. To our knowledge, this is the first report of pimecrolimus therapy in the treatment of pruritis secondary to DPLM. It is difficult to treat a rare disease such as DPLM when the pathogenesis is unknown, and many treatments have failed. Fortunately, DPLM and the other localized forms of LM are usually self-limited to the skin and have very little or no morbidity, leading some experts to believe that the disorder is unnecessary to treat.6 We believe that treatment is sometimes helpful. In our patient, the DPLM lesions were pruritic and located at a cosmetic area of the neck. The patient and dermatology staff decided to pursue a treatment plan. Therefore, even though localized LM lesions are typically benign, sometimes it is beneficial to treat them, especially if they cause irritating symptoms or cosmetic issues. 


Conclusion

 

 

DPLM is a rare variant of localized LM. DPLM can be diagnosed by a thorough history and physical examination; histologic proof of dermal mucin deposits; and ruling out other diseases with laboratory tests for serum protein, thyroid function, and, if the patient is at risk of diabetes mellitus, blood glucose levels. DPLM is a self-limited skin disease, and prognosis is generally good, but it typically persists long-term and may slowly progress. Treatment is usually unnecessary, but it may be recommended if the lesions are symptomatic or cause cosmetic issues. Unfortunately, few treatment plans have been shown to successfully treat DPLM. 

 

References

 

  1. Dubreuilh W. Fibromes miliaries folliculaires: sclerodermie consecutive. Arch Dermatol Syph. 1906;7:569-570.
  2. Montgomery H, Underwood LJ. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol. 1953;20:213-236.
  3. Truhan AP, Roenigk HH Jr. The cutaneous mucinoses. J Am Acad Dermatol. 1986;14:1-18.
  4. Rongioletti F, Rebora A. The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. J Am Acad Dermatol. 1991;24:265-270.
  5. Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23:257-267.
  6. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273-281.
  7. Coskey RJ, Mehregan A. Papular mucinosis. Int J Dermatol. 1977;16:741-744.
  8. Tay CH, Khoo OT. Papular mucinosis in chronic psoriatic erythroderma. report of a case. Arch Dermatol. 1970;102:304-308.
  9. Enerback L, Mobacken H. Lichen myxedematosus of urticarial type without paraproteinaemia. Dermatologica. 1976;152:309-315.
  10. Abd El-Aal H, Salem SZ, Salem A. Lichen myxedematosus: histochemical study. Dermatologica. 1981;162:273-276.
  11. Woerdeman MJ. Is collagenome erupt if a separate entity? Br J Dermatol. 1960;72:217-220.
  12. Podglajen-Wecxsteen O, Ehrsam E, Mailfer C, et al. Apropos of papulous mucinosis: acral persistent papular mucinosis or minor form of scleromyxedema [in French]. Ann Dermatol Venereol. 1992;119:834-836.
  13. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42:31-35.
  14. Boffa MJ, Ead RD. Spontaneous improvement of scleromyxoedema. Clin Exp Dermatol. 1995;20:157-160.
  15. Godby A, Bergstresser PR, Chaker B, et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289-294.
  16. Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28:105-108.
  17. Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol. 1998;38:760-761.
  18. Reynolds NJ, Collins CM, Burton JL. Discrete papular mucinosis responding to intralesional and topical steroids. Arch Dermatol. 1992;128:857-858.
  19. Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol. 1989;15:862-865.
  20. Montesu MA, Cottoni F, Sanna R, et al. Lichen myxedematosus associated with chronic hepatitis C: a case report. Acta Derm Venereol. 2001;81:67-68.
  21. Poswig A, Hinrichs M, Megahed M, et al. Discrete papular mucinosis—a rare subtype of lichen myxoedematosus. Clin Exp Dermatol. 2000;25:289-292.
  22.  
Article PDF
Author and Disclosure Information

 

Drs. Sulit, Harford, and O'Neill report no conflict of interest. The authors report off-label use of pimecrolimus for the treatment of discrete papular lichen myxedematosus. Dr. Sulit is staff Naval Flight Surgeon, Marine Corps Air Station, Branch Medical Clinic, Beaufort, South Carolina. Dr. Harford is Director, Dermatology Mohs Micrographic Surgery Laboratory, Department of Dermatology, Naval Medical Center, San Diego, California. Dr. O'Neill is staff dermatologist, Department of Dermatology, National Naval Medical Center, Bethesda, Maryland.

LT Daryl J. Sulit, MC, USNR; CDR Robert Harford, MC, USN; LCDR Jennifer T. O'Neill, MC, USN

Issue
Cutis - 75(2)
Publications
Page Number
105-112
Author and Disclosure Information

 

Drs. Sulit, Harford, and O'Neill report no conflict of interest. The authors report off-label use of pimecrolimus for the treatment of discrete papular lichen myxedematosus. Dr. Sulit is staff Naval Flight Surgeon, Marine Corps Air Station, Branch Medical Clinic, Beaufort, South Carolina. Dr. Harford is Director, Dermatology Mohs Micrographic Surgery Laboratory, Department of Dermatology, Naval Medical Center, San Diego, California. Dr. O'Neill is staff dermatologist, Department of Dermatology, National Naval Medical Center, Bethesda, Maryland.

LT Daryl J. Sulit, MC, USNR; CDR Robert Harford, MC, USN; LCDR Jennifer T. O'Neill, MC, USN

Author and Disclosure Information

 

Drs. Sulit, Harford, and O'Neill report no conflict of interest. The authors report off-label use of pimecrolimus for the treatment of discrete papular lichen myxedematosus. Dr. Sulit is staff Naval Flight Surgeon, Marine Corps Air Station, Branch Medical Clinic, Beaufort, South Carolina. Dr. Harford is Director, Dermatology Mohs Micrographic Surgery Laboratory, Department of Dermatology, Naval Medical Center, San Diego, California. Dr. O'Neill is staff dermatologist, Department of Dermatology, National Naval Medical Center, Bethesda, Maryland.

LT Daryl J. Sulit, MC, USNR; CDR Robert Harford, MC, USN; LCDR Jennifer T. O'Neill, MC, USN

Article PDF
Article PDF

Lichen myxedematosus (LM), also called papular mucinosis, was first described by Dubreuilh1 in 1906 and later classified by Montgomery and Underwood2 in 1953. LMs are a group of localized or generalized papular eruptions of unknown etiology categorized as cutaneous mucinoses in which dermal mucin deposition is the distinctive histologic feature.3-5 LM has no relation to endocrine gland disorders, particularly thyroid disease.2,3,6 In their landmark paper, Montgomery and Underwood2 classified 4 clinical types of LM: (1) generalized lichenoid papular eruption, which is also called scleromyxedema, (2) discrete papular form, (3) localized to generalized lichenoid plaques, and (4) urticarial plaques and nodular eruptions that usually evolve into the generalized lichenoid form. In 2001, Rongioletti and Rebora6 updated the classification system. The articles by Montgomery and Underwood2 and Rongioletti and Rebora6 both agree with the existence of the discrete papular form, also called discrete papular LM (DPLM). According to Rongioletti and Rebora,6 DPLM has only been reported in the medical literature 8 times,1,2,7-12 This is unlike scleromyxedema, the most common type of LM, which has been documented in more than 110 cases.6 In this case report, we describe an interesting case of DPLM that was localized to the neck of our patient, and we review the English medical literature. 


Case Report

An 80-year-old black woman presented to our clinic with a 2-month history of a pruritic eruption localized to her neck. Multiple topical steroids and antihistamines had been used without any decrease in the eruption or the pruritus. The woman's medical history was significant for gastric cancer status post a partial gastrectomy 7 years prior, pseudotumor cerebri, hypertension, and osteoporosis. She is followed regularly for these conditions, which are stable. Her medications included acetazolamide, atenolol, nifedipine, rabeprazole sodium, fluoxetine, oxybutynin chloride, alendronate sodium, docusate calcium, and a multivitamin. Prior to the onset of this eruption, the patient had a change in the acetazolamide formulation, which was initially thought to be the culprit. Although she returned to the original formulation for longer than a month, she had no resolution of the symptoms. At that time, she sought evaluation in our clinic. On physical examination, multiple 2- to 4-mm discrete, flesh-colored shiny papules without scale were present over the patient's bilateral and posterior neck (Figure 1). Results of 2 punch biopsies showed splaying of the collagen with mucin present diffusely throughout the dermis. No increase in the number of fibroblasts was seen (Figure 2). Results of colloidal iron stain showed positive results in the papillary dermis and showed mucin mildly throughout the deep dermis (Figure 3), supporting the diagnosis of LM. Complete blood count, chemistry panel, liver function, thyrotropin, and serum protein test results were all within reference range. Pimecrolimus cream has been effective in treating our patient's pruritus. We have followed her for 14 months, and the lesions have remained localized to her neck, with continued normal thyrotropin and serum protein values.


Comment

In 2001, Rongioletti and Rebora6 revised the classification system of LM, categorizing it into 3 broad subsets: (1) generalized papular and sclerodermoid, (2) localized LM, and (3) atypical forms. The first subset, generalized papular and sclerodermoid, represents scleromyxedema. Diagnosis requires a generalized papular and sclerodermoid eruption, monoclonal gammopathy (paraproteinemia), no evidence of thyroid dysfunction, and a histologic triad of fibroblast proliferation, fibrosis, and mucin deposition.6 Scleromyxedema is associated with many systemic disorders that may include numerous organ systems.6,13 Although spontaneous resolution has been reported,14 scleromyxedema typically is a long-term and disfiguring disease6,13 associated with variable morbidity and mortality.15,16 The criteria for diagnosing the subset of localized LM requires a papular eruption, deposits of mucin with variable fibroblast growth, absence of paraproteinemia, and absence of thyroid dysfunction.6 There are 5 subtypes6: DPLM,2,7-9,17-21 acral persistent papular mucinosis (APPM),22-27 cutaneous mucinosis of infancy,28-31 self-healing papular mucinosis (SHPM),32-36 and nodular LM.37,38 All subtypes show small, firm, waxy papules limited to a few areas of the skin, which may coalesce and form nodules or plaques. DPLM can involve any site on the body. APPM exclusively involves both extensor surfaces of the distal upper extremities. Cutaneous mucinosis of infancy is a pediatric variant of DPLM or APPM. SHPM has spontaneous resolution. Nodular LM is characterized by a predominance of nodules.6 All subtypes except for SHPM typically persist long-term. Systemic symptoms were only reported in SHPM.32,33 In general, localized LM is self-limited and associated with a good prognosis.6 The histologic features of LM are summarized in Table 1.5 The pathology lies within the dermis for all types of this disease, and the epidermis is essentially normal.5 The types of LM can be distinguished from one another by 3 histologic clues: (1) mucin distribution pattern, (2) dermal level of mucin deposits, and (3) some extra findings.5 Differentiation can be additionally aided by observing the number of fibroblasts. Common mucin stains include colloidal iron, mucicarmine, and alcian blue at pH 2.5 (but not pH 0.5); common metachromatic mucin stains include toluidine blue, thionine, and methylene blue.3

 

 

DPLM is a subtype of localized LM.2,6 Although the lesions can involve any site, DPLM is typically distributed symmetrically to the trunk and limbs. The skin lesions have been described as a variable number of firm, smooth, waxy, or flesh-colored papules 2 to 5 mm in size. Normal serum protein and thyroid function test results verify the diagnosis of DPLM.6 Because Montgomery and Underwood2 originally defined LM as having no relation to any endocrine gland disturbance, we recommend additional random chemistry panel or fasting blood glucose laboratory tests if there is any question that a patient may have diabetes mellitus. Histologically, DPLM may have a diffuse or local pattern of mucin distribution involving the upper and mid reticular dermis. The involved dermis typically shows edema. The amount of fibroblast proliferation is variable. When compared with scleromyxedema, DPLM has no collagen deposition or sclerosis and a lesser amount of fibroblast proliferation.5-7 Some argue that DPLM and APPM are closely related variants.25,27 However, we believe that DPLM and APPM are distinct subtypes of localized LM. DPLM typically affects men (Table 2) and its lesions may be erythematous, larger, and include areas other than the distal upper extremities.4,23,24 In comparison, APPM has an overwhelming female-to-male ratio of 4.7:1.6 APPM also exclusively involves the back of the hands, extensor surface of the wrists, and sometimes the distal forearms.4,6,23 Histologically, APPM typically has more focal mucin deposits, which spare a subepidermal grenz zone, and a normal number of fibroblasts; DPLM has mucin deposits that are more diffuse (compared with APPM), have a variable number of increased fibroblasts, and have an irregular arrangement of collagen bundles.4-6,23

Table 2 summarizes the main features of the 10 DPLM cases reported in the English medical literature.2,7-9,17-21 Our criteria required there be no evidence of paraproteinemia, no history or laboratory evidence of any endocrine disease, no history of human immunodeficiency virus infection, histologic proof of dermal mucin deposits, and specific gross descriptions consistent with DPLM. It should be noted that only 4 of the 8 DPLM cases originally cited by Rongioletti and Rebora6 were included in Table 2. Four cases were excluded because 2 reports were written in French,1,12 1 report included a patient with diabetes mellitus,10 and another did not perform a necessary laboratory test to rule out thyroid disease.11 Other cases were excluded because they did not fulfill our criteria.39,40 Among the 10 DPLM patients summarized, 7 were men. The mean age of the group was 51.3 years. Only 3 of the 10 cases reported information on the patient's ethnicity: one was Caucasian,7 one was Asian,8 and our patient was African American. Nine of the 10 cases reported no evidence of paraproteinemia. The single case2 that did not report this finding was published before an association between LM and paraproteinemia was known in the 1960s.41 All 10 cases reported thyroid function test results within reference range. Only 3 of the 10 patients had symptomatic skin lesions, which were mainly pruritus. No systemic symptoms were noted. Three of the 10 patients had solitary skin lesions on areas other than the typical trunk and limbs. One patient had skin lesions only on his lumbar region, another had facial lesions, and our patient had lesions on her neck. Seven of the 10 patients had comorbid medical disorders, including hypertension, migraines, psoriatic erythroderma, psoriasis, seizures, gastric cancer in remission, pseudotumor cerebri, osteoporosis, and hepatitis C. Only hepatitis C was comorbid with more than one DPLM patient.17,20 This may be a coincidence because one patient developed DPLM after contracting hepatitis C,20, while the other patient developed it before contracting hepatitis C.17 Psychiatric illness was limited to depression and was found in 2 cases.20,21 No DPLM cases progressed to scleromyxedema, and none have been reported in the literature.5,6 DPLM rarely resolves on its own. Spontaneous resolution did not occur in any of the 10 reported DPLM cases, and only 2 patients were treated successfully. In Reynolds et al,18 the patient responded to therapy with intralesional corticosteroid injections and flurandrenolide-impregnated tape. In Kaymen et al,19 a patient was treated with a CO2 laser and postoperative intralesional corticosteroid injections. There was no growth after one year. All the other DPLM cases did not have effective therapy, lacked specific details of improvement, or did not report this information.2,7-9,17,20,21 Only Tay and Khoo,8 Enerback and Mobacken,9 and Kaymen et al19 commented on which therapies failed (oral thyroxine, topical corticosteroids, and shave excision, respectively). Our patient complained of persistent itching that did not respond to initial treatment with topical steroids and antihistamine medications. She later received pruritic relief with pimecrolimus cream therapy. However, the skin lesions remained. To our knowledge, this is the first report of pimecrolimus therapy in the treatment of pruritis secondary to DPLM. It is difficult to treat a rare disease such as DPLM when the pathogenesis is unknown, and many treatments have failed. Fortunately, DPLM and the other localized forms of LM are usually self-limited to the skin and have very little or no morbidity, leading some experts to believe that the disorder is unnecessary to treat.6 We believe that treatment is sometimes helpful. In our patient, the DPLM lesions were pruritic and located at a cosmetic area of the neck. The patient and dermatology staff decided to pursue a treatment plan. Therefore, even though localized LM lesions are typically benign, sometimes it is beneficial to treat them, especially if they cause irritating symptoms or cosmetic issues. 


Conclusion

 

 

DPLM is a rare variant of localized LM. DPLM can be diagnosed by a thorough history and physical examination; histologic proof of dermal mucin deposits; and ruling out other diseases with laboratory tests for serum protein, thyroid function, and, if the patient is at risk of diabetes mellitus, blood glucose levels. DPLM is a self-limited skin disease, and prognosis is generally good, but it typically persists long-term and may slowly progress. Treatment is usually unnecessary, but it may be recommended if the lesions are symptomatic or cause cosmetic issues. Unfortunately, few treatment plans have been shown to successfully treat DPLM. 

 

Lichen myxedematosus (LM), also called papular mucinosis, was first described by Dubreuilh1 in 1906 and later classified by Montgomery and Underwood2 in 1953. LMs are a group of localized or generalized papular eruptions of unknown etiology categorized as cutaneous mucinoses in which dermal mucin deposition is the distinctive histologic feature.3-5 LM has no relation to endocrine gland disorders, particularly thyroid disease.2,3,6 In their landmark paper, Montgomery and Underwood2 classified 4 clinical types of LM: (1) generalized lichenoid papular eruption, which is also called scleromyxedema, (2) discrete papular form, (3) localized to generalized lichenoid plaques, and (4) urticarial plaques and nodular eruptions that usually evolve into the generalized lichenoid form. In 2001, Rongioletti and Rebora6 updated the classification system. The articles by Montgomery and Underwood2 and Rongioletti and Rebora6 both agree with the existence of the discrete papular form, also called discrete papular LM (DPLM). According to Rongioletti and Rebora,6 DPLM has only been reported in the medical literature 8 times,1,2,7-12 This is unlike scleromyxedema, the most common type of LM, which has been documented in more than 110 cases.6 In this case report, we describe an interesting case of DPLM that was localized to the neck of our patient, and we review the English medical literature. 


Case Report

An 80-year-old black woman presented to our clinic with a 2-month history of a pruritic eruption localized to her neck. Multiple topical steroids and antihistamines had been used without any decrease in the eruption or the pruritus. The woman's medical history was significant for gastric cancer status post a partial gastrectomy 7 years prior, pseudotumor cerebri, hypertension, and osteoporosis. She is followed regularly for these conditions, which are stable. Her medications included acetazolamide, atenolol, nifedipine, rabeprazole sodium, fluoxetine, oxybutynin chloride, alendronate sodium, docusate calcium, and a multivitamin. Prior to the onset of this eruption, the patient had a change in the acetazolamide formulation, which was initially thought to be the culprit. Although she returned to the original formulation for longer than a month, she had no resolution of the symptoms. At that time, she sought evaluation in our clinic. On physical examination, multiple 2- to 4-mm discrete, flesh-colored shiny papules without scale were present over the patient's bilateral and posterior neck (Figure 1). Results of 2 punch biopsies showed splaying of the collagen with mucin present diffusely throughout the dermis. No increase in the number of fibroblasts was seen (Figure 2). Results of colloidal iron stain showed positive results in the papillary dermis and showed mucin mildly throughout the deep dermis (Figure 3), supporting the diagnosis of LM. Complete blood count, chemistry panel, liver function, thyrotropin, and serum protein test results were all within reference range. Pimecrolimus cream has been effective in treating our patient's pruritus. We have followed her for 14 months, and the lesions have remained localized to her neck, with continued normal thyrotropin and serum protein values.


Comment

In 2001, Rongioletti and Rebora6 revised the classification system of LM, categorizing it into 3 broad subsets: (1) generalized papular and sclerodermoid, (2) localized LM, and (3) atypical forms. The first subset, generalized papular and sclerodermoid, represents scleromyxedema. Diagnosis requires a generalized papular and sclerodermoid eruption, monoclonal gammopathy (paraproteinemia), no evidence of thyroid dysfunction, and a histologic triad of fibroblast proliferation, fibrosis, and mucin deposition.6 Scleromyxedema is associated with many systemic disorders that may include numerous organ systems.6,13 Although spontaneous resolution has been reported,14 scleromyxedema typically is a long-term and disfiguring disease6,13 associated with variable morbidity and mortality.15,16 The criteria for diagnosing the subset of localized LM requires a papular eruption, deposits of mucin with variable fibroblast growth, absence of paraproteinemia, and absence of thyroid dysfunction.6 There are 5 subtypes6: DPLM,2,7-9,17-21 acral persistent papular mucinosis (APPM),22-27 cutaneous mucinosis of infancy,28-31 self-healing papular mucinosis (SHPM),32-36 and nodular LM.37,38 All subtypes show small, firm, waxy papules limited to a few areas of the skin, which may coalesce and form nodules or plaques. DPLM can involve any site on the body. APPM exclusively involves both extensor surfaces of the distal upper extremities. Cutaneous mucinosis of infancy is a pediatric variant of DPLM or APPM. SHPM has spontaneous resolution. Nodular LM is characterized by a predominance of nodules.6 All subtypes except for SHPM typically persist long-term. Systemic symptoms were only reported in SHPM.32,33 In general, localized LM is self-limited and associated with a good prognosis.6 The histologic features of LM are summarized in Table 1.5 The pathology lies within the dermis for all types of this disease, and the epidermis is essentially normal.5 The types of LM can be distinguished from one another by 3 histologic clues: (1) mucin distribution pattern, (2) dermal level of mucin deposits, and (3) some extra findings.5 Differentiation can be additionally aided by observing the number of fibroblasts. Common mucin stains include colloidal iron, mucicarmine, and alcian blue at pH 2.5 (but not pH 0.5); common metachromatic mucin stains include toluidine blue, thionine, and methylene blue.3

 

 

DPLM is a subtype of localized LM.2,6 Although the lesions can involve any site, DPLM is typically distributed symmetrically to the trunk and limbs. The skin lesions have been described as a variable number of firm, smooth, waxy, or flesh-colored papules 2 to 5 mm in size. Normal serum protein and thyroid function test results verify the diagnosis of DPLM.6 Because Montgomery and Underwood2 originally defined LM as having no relation to any endocrine gland disturbance, we recommend additional random chemistry panel or fasting blood glucose laboratory tests if there is any question that a patient may have diabetes mellitus. Histologically, DPLM may have a diffuse or local pattern of mucin distribution involving the upper and mid reticular dermis. The involved dermis typically shows edema. The amount of fibroblast proliferation is variable. When compared with scleromyxedema, DPLM has no collagen deposition or sclerosis and a lesser amount of fibroblast proliferation.5-7 Some argue that DPLM and APPM are closely related variants.25,27 However, we believe that DPLM and APPM are distinct subtypes of localized LM. DPLM typically affects men (Table 2) and its lesions may be erythematous, larger, and include areas other than the distal upper extremities.4,23,24 In comparison, APPM has an overwhelming female-to-male ratio of 4.7:1.6 APPM also exclusively involves the back of the hands, extensor surface of the wrists, and sometimes the distal forearms.4,6,23 Histologically, APPM typically has more focal mucin deposits, which spare a subepidermal grenz zone, and a normal number of fibroblasts; DPLM has mucin deposits that are more diffuse (compared with APPM), have a variable number of increased fibroblasts, and have an irregular arrangement of collagen bundles.4-6,23

Table 2 summarizes the main features of the 10 DPLM cases reported in the English medical literature.2,7-9,17-21 Our criteria required there be no evidence of paraproteinemia, no history or laboratory evidence of any endocrine disease, no history of human immunodeficiency virus infection, histologic proof of dermal mucin deposits, and specific gross descriptions consistent with DPLM. It should be noted that only 4 of the 8 DPLM cases originally cited by Rongioletti and Rebora6 were included in Table 2. Four cases were excluded because 2 reports were written in French,1,12 1 report included a patient with diabetes mellitus,10 and another did not perform a necessary laboratory test to rule out thyroid disease.11 Other cases were excluded because they did not fulfill our criteria.39,40 Among the 10 DPLM patients summarized, 7 were men. The mean age of the group was 51.3 years. Only 3 of the 10 cases reported information on the patient's ethnicity: one was Caucasian,7 one was Asian,8 and our patient was African American. Nine of the 10 cases reported no evidence of paraproteinemia. The single case2 that did not report this finding was published before an association between LM and paraproteinemia was known in the 1960s.41 All 10 cases reported thyroid function test results within reference range. Only 3 of the 10 patients had symptomatic skin lesions, which were mainly pruritus. No systemic symptoms were noted. Three of the 10 patients had solitary skin lesions on areas other than the typical trunk and limbs. One patient had skin lesions only on his lumbar region, another had facial lesions, and our patient had lesions on her neck. Seven of the 10 patients had comorbid medical disorders, including hypertension, migraines, psoriatic erythroderma, psoriasis, seizures, gastric cancer in remission, pseudotumor cerebri, osteoporosis, and hepatitis C. Only hepatitis C was comorbid with more than one DPLM patient.17,20 This may be a coincidence because one patient developed DPLM after contracting hepatitis C,20, while the other patient developed it before contracting hepatitis C.17 Psychiatric illness was limited to depression and was found in 2 cases.20,21 No DPLM cases progressed to scleromyxedema, and none have been reported in the literature.5,6 DPLM rarely resolves on its own. Spontaneous resolution did not occur in any of the 10 reported DPLM cases, and only 2 patients were treated successfully. In Reynolds et al,18 the patient responded to therapy with intralesional corticosteroid injections and flurandrenolide-impregnated tape. In Kaymen et al,19 a patient was treated with a CO2 laser and postoperative intralesional corticosteroid injections. There was no growth after one year. All the other DPLM cases did not have effective therapy, lacked specific details of improvement, or did not report this information.2,7-9,17,20,21 Only Tay and Khoo,8 Enerback and Mobacken,9 and Kaymen et al19 commented on which therapies failed (oral thyroxine, topical corticosteroids, and shave excision, respectively). Our patient complained of persistent itching that did not respond to initial treatment with topical steroids and antihistamine medications. She later received pruritic relief with pimecrolimus cream therapy. However, the skin lesions remained. To our knowledge, this is the first report of pimecrolimus therapy in the treatment of pruritis secondary to DPLM. It is difficult to treat a rare disease such as DPLM when the pathogenesis is unknown, and many treatments have failed. Fortunately, DPLM and the other localized forms of LM are usually self-limited to the skin and have very little or no morbidity, leading some experts to believe that the disorder is unnecessary to treat.6 We believe that treatment is sometimes helpful. In our patient, the DPLM lesions were pruritic and located at a cosmetic area of the neck. The patient and dermatology staff decided to pursue a treatment plan. Therefore, even though localized LM lesions are typically benign, sometimes it is beneficial to treat them, especially if they cause irritating symptoms or cosmetic issues. 


Conclusion

 

 

DPLM is a rare variant of localized LM. DPLM can be diagnosed by a thorough history and physical examination; histologic proof of dermal mucin deposits; and ruling out other diseases with laboratory tests for serum protein, thyroid function, and, if the patient is at risk of diabetes mellitus, blood glucose levels. DPLM is a self-limited skin disease, and prognosis is generally good, but it typically persists long-term and may slowly progress. Treatment is usually unnecessary, but it may be recommended if the lesions are symptomatic or cause cosmetic issues. Unfortunately, few treatment plans have been shown to successfully treat DPLM. 

 

References

 

  1. Dubreuilh W. Fibromes miliaries folliculaires: sclerodermie consecutive. Arch Dermatol Syph. 1906;7:569-570.
  2. Montgomery H, Underwood LJ. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol. 1953;20:213-236.
  3. Truhan AP, Roenigk HH Jr. The cutaneous mucinoses. J Am Acad Dermatol. 1986;14:1-18.
  4. Rongioletti F, Rebora A. The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. J Am Acad Dermatol. 1991;24:265-270.
  5. Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23:257-267.
  6. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273-281.
  7. Coskey RJ, Mehregan A. Papular mucinosis. Int J Dermatol. 1977;16:741-744.
  8. Tay CH, Khoo OT. Papular mucinosis in chronic psoriatic erythroderma. report of a case. Arch Dermatol. 1970;102:304-308.
  9. Enerback L, Mobacken H. Lichen myxedematosus of urticarial type without paraproteinaemia. Dermatologica. 1976;152:309-315.
  10. Abd El-Aal H, Salem SZ, Salem A. Lichen myxedematosus: histochemical study. Dermatologica. 1981;162:273-276.
  11. Woerdeman MJ. Is collagenome erupt if a separate entity? Br J Dermatol. 1960;72:217-220.
  12. Podglajen-Wecxsteen O, Ehrsam E, Mailfer C, et al. Apropos of papulous mucinosis: acral persistent papular mucinosis or minor form of scleromyxedema [in French]. Ann Dermatol Venereol. 1992;119:834-836.
  13. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42:31-35.
  14. Boffa MJ, Ead RD. Spontaneous improvement of scleromyxoedema. Clin Exp Dermatol. 1995;20:157-160.
  15. Godby A, Bergstresser PR, Chaker B, et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289-294.
  16. Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28:105-108.
  17. Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol. 1998;38:760-761.
  18. Reynolds NJ, Collins CM, Burton JL. Discrete papular mucinosis responding to intralesional and topical steroids. Arch Dermatol. 1992;128:857-858.
  19. Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol. 1989;15:862-865.
  20. Montesu MA, Cottoni F, Sanna R, et al. Lichen myxedematosus associated with chronic hepatitis C: a case report. Acta Derm Venereol. 2001;81:67-68.
  21. Poswig A, Hinrichs M, Megahed M, et al. Discrete papular mucinosis—a rare subtype of lichen myxoedematosus. Clin Exp Dermatol. 2000;25:289-292.
  22.  
References

 

  1. Dubreuilh W. Fibromes miliaries folliculaires: sclerodermie consecutive. Arch Dermatol Syph. 1906;7:569-570.
  2. Montgomery H, Underwood LJ. Lichen myxedematosus (differentiation from cutaneous myxedemas or mucoid states). J Invest Dermatol. 1953;20:213-236.
  3. Truhan AP, Roenigk HH Jr. The cutaneous mucinoses. J Am Acad Dermatol. 1986;14:1-18.
  4. Rongioletti F, Rebora A. The new cutaneous mucinoses: a review with an up-to-date classification of cutaneous mucinoses. J Am Acad Dermatol. 1991;24:265-270.
  5. Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol. 2001;23:257-267.
  6. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol. 2001;44:273-281.
  7. Coskey RJ, Mehregan A. Papular mucinosis. Int J Dermatol. 1977;16:741-744.
  8. Tay CH, Khoo OT. Papular mucinosis in chronic psoriatic erythroderma. report of a case. Arch Dermatol. 1970;102:304-308.
  9. Enerback L, Mobacken H. Lichen myxedematosus of urticarial type without paraproteinaemia. Dermatologica. 1976;152:309-315.
  10. Abd El-Aal H, Salem SZ, Salem A. Lichen myxedematosus: histochemical study. Dermatologica. 1981;162:273-276.
  11. Woerdeman MJ. Is collagenome erupt if a separate entity? Br J Dermatol. 1960;72:217-220.
  12. Podglajen-Wecxsteen O, Ehrsam E, Mailfer C, et al. Apropos of papulous mucinosis: acral persistent papular mucinosis or minor form of scleromyxedema [in French]. Ann Dermatol Venereol. 1992;119:834-836.
  13. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol. 2003;42:31-35.
  14. Boffa MJ, Ead RD. Spontaneous improvement of scleromyxoedema. Clin Exp Dermatol. 1995;20:157-160.
  15. Godby A, Bergstresser PR, Chaker B, et al. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol. 1998;38:289-294.
  16. Webster GF, Matsuoka LY, Burchmore D. The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol. 1993;28:105-108.
  17. Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol. 1998;38:760-761.
  18. Reynolds NJ, Collins CM, Burton JL. Discrete papular mucinosis responding to intralesional and topical steroids. Arch Dermatol. 1992;128:857-858.
  19. Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol. 1989;15:862-865.
  20. Montesu MA, Cottoni F, Sanna R, et al. Lichen myxedematosus associated with chronic hepatitis C: a case report. Acta Derm Venereol. 2001;81:67-68.
  21. Poswig A, Hinrichs M, Megahed M, et al. Discrete papular mucinosis—a rare subtype of lichen myxoedematosus. Clin Exp Dermatol. 2000;25:289-292.
  22.  
Issue
Cutis - 75(2)
Issue
Cutis - 75(2)
Page Number
105-112
Page Number
105-112
Publications
Publications
Article Type
Display Headline
Discrete Papular Form of Lichen Myxedematosus: A Case Report and Review of the Literature
Display Headline
Discrete Papular Form of Lichen Myxedematosus: A Case Report and Review of the Literature
Disallow All Ads
Article PDF Media